Notable Tuesday Option Activity: TGTX, SPOT, TECH

Significant options activity was recorded in Spotify (SPOT) and Bio-Techne (TECH) today: SPOT saw 10,438 contracts (~1.0m underlying shares), about 64.7% of its one‑month average daily volume, with particularly heavy put activity at the $530 Jan 16, 2026 strike (1,006 contracts, ~100,600 shares). TECH traded 10,721 contracts (~1.1m underlying shares), ~64% of its one‑month average, driven by large put volume at the $55 Feb 20, 2026 strike (5,212 contracts, ~521,200 shares). The concentration of put activity suggests bearish positioning or hedging that could exert downside pressure on the individual equities if flows continue.

Analysis

Market structure: the concentrated put flow in SPOT (1,006 Jan‑16‑2026 $530 puts ≈100.6k shares) and TECH (5,212 Feb‑20‑2026 $55 puts ≈521.2k shares) implies large directional or hedged bearish demand that equals ~64% of each stock’s ADV — enough to move intra‑day liquidity and skew. Beneficiaries are options sellers and liquidity providers who can collect premium; losers are long equity holders facing transient delta‑hedging pressure and higher borrow costs if positions get shorted. Expect implied volatility skew to steepen and realized spot volatility to rise near large block hedging windows, compressing bid liquidity and widening spreads.

Risk assessment: tail risks include a binary negative catalyst (adverse trial results for TECH or ad/ARPU misses for SPOT) that converts option bets into forced equity selling, and a market‑maker deleveraging event that amplifies price moves. Immediate (days) risk is gamma/delta hedging around these trades; short‑term (weeks‑months) is persistent IV elevation into the listed expiries; long‑term (quarters) reverts to fundamentals unless repeated flows recur. Hidden dependencies: flows may be structured hedges (collars, convertible hedging), not pure directional bets — monitor changes in open interest vs. traded volume and stock borrow rates for true positioning.

Trade implications: favor tightly defined option structures over naked exposure. For TECH, a Feb‑20‑2026 55/45 put debit spread limits downside risk while capturing >2x payoff if TECH drops ≥15% by expiry; size 0.5–1.0% of portfolio. For SPOT, consider a Jan‑16‑2026 530/480 put spread (0.25–0.75% portfolio) or a tactical short triggered if SPOT breaks its 5‑day VWAP with >2% daily decline; trim on mean reversion or if IV contracts >30%.

Contrarian angles: heavy put volume can be hedge flow that creates overstated bearish headlines — market‑maker delta hedging may produce transient overshoots and mean reversion within 1–4 weeks. If TECH implied vol spikes >50% while open interest concentrates in one strike, selling a portion of that skew (iron put fly or broken‑wing butterfly) can be profitable if fundamentals are intact. Key watchables that expose mispricing: borrow rate >5%, OI change >30% day‑over‑day, and upcoming corporate/clinical catalysts within 30–90 days.

Key Decisions for Investors

• TECH directional (defined risk): buy Feb‑20‑2026 55/45 put debit spread (buy 55p, sell 45p) sized to 0.5–1.0% of portfolio; target payoff if TECH down ≥15% by expiry; exit/stop‑loss: close if TECH >70 or if IV contracts >30% from entry; close by Feb 15, 2026 at latest.
• SPOT tactical (defined risk or short trigger): purchase Jan‑16‑2026 530/480 put spread sized 0.25–0.75% portfolio OR initiate a 1–2% notional short equity position only if SPOT breaks below its 5‑day VWAP with >2% intraday fall; cover/close by Jan 12–15, 2026 or if SPOT rallies back above 5‑day VWAP.
• Relative trade (pair): short TECH 0.75% notional vs long IBB or a large‑cap biotech ETF 0.75% notional to isolate idiosyncratic downside, maintain until Feb 20, 2026 or until TECH fundamentals or borrow cost normalize (close if borrow rate >150 bps above baseline).
• Risk posture and monitoring: raise cash/Treasury exposure by 2–4% and monitor three triggers daily — change in open interest >30% (24h), borrow rate >5% (absolute) or >150 bps jump, and IV move >30% — any trigger mandates re‑assessment/scale‑down within 48 hours.